+

WO2007009758A3 - 2r,4s) -4- (4-acetyl-3-hydroxy-1-piperazinyl) -n- { (1r) -1- [3, 5-bis (trifluoromethyl) phenyl] ethyl} -2- (4-fluoro-2-methylphenyl) -n-methyl-1-piperidine-carboxamide as tachykinin receptor antagonist - Google Patents

2r,4s) -4- (4-acetyl-3-hydroxy-1-piperazinyl) -n- { (1r) -1- [3, 5-bis (trifluoromethyl) phenyl] ethyl} -2- (4-fluoro-2-methylphenyl) -n-methyl-1-piperidine-carboxamide as tachykinin receptor antagonist Download PDF

Info

Publication number
WO2007009758A3
WO2007009758A3 PCT/EP2006/007080 EP2006007080W WO2007009758A3 WO 2007009758 A3 WO2007009758 A3 WO 2007009758A3 EP 2006007080 W EP2006007080 W EP 2006007080W WO 2007009758 A3 WO2007009758 A3 WO 2007009758A3
Authority
WO
WIPO (PCT)
Prior art keywords
carboxamide
piperazinyl
methylphenyl
piperidine
trifluoromethyl
Prior art date
Application number
PCT/EP2006/007080
Other languages
French (fr)
Other versions
WO2007009758A2 (en
Inventor
Silvia Martinucci
Andrew Roberts
Original Assignee
Glaxo Group Ltd
Silvia Martinucci
Andrew Roberts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Silvia Martinucci, Andrew Roberts filed Critical Glaxo Group Ltd
Publication of WO2007009758A2 publication Critical patent/WO2007009758A2/en
Publication of WO2007009758A3 publication Critical patent/WO2007009758A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, process for their preparation, their use in the treatment of conditions mediated by tachykinins and pharmaceutical compositions containing them.
PCT/EP2006/007080 2005-07-18 2006-07-14 2r,4s) -4- (4-acetyl-3-hydroxy-1-piperazinyl) -n- { (1r) -1- [3, 5-bis (trifluoromethyl) phenyl] ethyl} -2- (4-fluoro-2-methylphenyl) -n-methyl-1-piperidine-carboxamide as tachykinin receptor antagonist WO2007009758A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0514705.3A GB0514705D0 (en) 2005-07-18 2005-07-18 Chemical compounds
GB0514705.3 2005-07-18

Publications (2)

Publication Number Publication Date
WO2007009758A2 WO2007009758A2 (en) 2007-01-25
WO2007009758A3 true WO2007009758A3 (en) 2007-04-19

Family

ID=34897390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/007080 WO2007009758A2 (en) 2005-07-18 2006-07-14 2r,4s) -4- (4-acetyl-3-hydroxy-1-piperazinyl) -n- { (1r) -1- [3, 5-bis (trifluoromethyl) phenyl] ethyl} -2- (4-fluoro-2-methylphenyl) -n-methyl-1-piperidine-carboxamide as tachykinin receptor antagonist

Country Status (2)

Country Link
GB (1) GB0514705D0 (en)
WO (1) WO2007009758A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0812849D0 (en) * 2008-07-14 2008-08-20 Glaxo Wellcome Mfg Pte Ltd Novel compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032867A1 (en) * 2000-10-17 2002-04-25 Glaxo Group Limited Chemical compounds
WO2003066621A1 (en) * 2002-02-08 2003-08-14 Glaxo Group Limited Piperidine derivatives and their use as antagonists of tachykinins
WO2003099787A1 (en) * 2002-05-29 2003-12-04 Tanabe Seiyaku Co., Ltd. Novel piperidine compound
WO2004110996A1 (en) * 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032867A1 (en) * 2000-10-17 2002-04-25 Glaxo Group Limited Chemical compounds
WO2003066621A1 (en) * 2002-02-08 2003-08-14 Glaxo Group Limited Piperidine derivatives and their use as antagonists of tachykinins
WO2003099787A1 (en) * 2002-05-29 2003-12-04 Tanabe Seiyaku Co., Ltd. Novel piperidine compound
WO2004110996A1 (en) * 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist

Also Published As

Publication number Publication date
WO2007009758A2 (en) 2007-01-25
GB0514705D0 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
EP2286825A3 (en) Melanocortin receptor ligands
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007120284A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
EA200970585A1 (en) BENZAMIDE DERIVATIVES AS AGONISTS OF EP RECEPTORS
PL2054411T3 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
EP2397476A3 (en) Indole derivative having PGD2 receptor antagonist activity
EA200801998A1 (en) ПИРДДИН [3,4-b] ПИРАЗИНОНЫ
EP1861357A4 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
IL179599A0 (en) Glucagon receptor antagonists, preparation and therapeutic uses
TNSN07313A1 (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
SI1735278T1 (en) Histamine h3 receptor agents, preparation and therapeutic uses
WO2007114855A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
EP1741712A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol
WO2006071740A3 (en) 5ht2c receptor modulator compositions and methods of use
WO2008121348A8 (en) Peripheral opioid receptor antagonists and uses thereof
EP2202222A3 (en) Indene derivatives, their preparation and use as medicaments
NO20071314L (en) Peptidic vasopressin receptor agonists
MY145919A (en) Pharmaceutical formulation comprising neurokinin antagonist
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2005094810A3 (en) Novel pharmaceutical compositions
MX2009006010A (en) Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases.
NO20060191L (en) 1- (alkylaminoalkyl-pyrolidine / piperidinyl) 2,2-diphenylacetamide derivatives as muscarinic receptor agonists
WO2009032843A3 (en) Deuterated ethambutols and their use
MX2007011374A (en) Pyrrolidine derivatives as histamine h3 receptor antagonists.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06762682

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06762682

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载